Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UX-GIP001 in Adult Patients With Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
NCT07244328Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Nov 2025
- Primary completion
- Nov 2028
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UX-GIP001 in mesial temporal lobe epilepsy (MTLE), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Incidence and severity of Adverse Events (AEs)/Serious Adverse Events (SAEs) at 2 years. Started Nov 2025; status: recruiting.
02
Drugs
UX-GIP001
03
Conditions
mesial temporal lobe epilepsy (MTLE)
Beyond the preview
Go deeper on NCT07244328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07244328.